Physician profile
Punit Kumar Sarna
NPI 1659553923
$5,159.21
in general payments reported to CMS, 2019-2025
25 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $802 · 2021: $1,402 · 2022: $347 · 2023: $1,021 · 2024: $563 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $555.39 | 2020-2023 | Nexletol |
| Abbott Laboratories | $541.26 | 2019-2023 | Cardiomems, Jot Dx |
| Novartis Pharmaceuticals Corporation | $472.18 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $331.79 | 2019-2021 | |
| Novo Nordisk INC | $316.31 | 2021-2023 | |
| Bardy Diagnostics, INC. | $282.77 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $276.92 | 2019-2024 | Lifevest |
| Heartflow, INC. | $272.05 | 2025 | |
| Pfizer INC. | $260.92 | 2019-2024 | |
| Philips North America LLC | $254.52 | 2023-2024 | (5044) Mcot, (5050) Ext Holter |
| Astellas Pharma US INC | $224.41 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.56 | 2023 | Jardiance |
| Amgen INC. | $181.88 | 2019-2023 | Repatha |
| Kiniksa Pharmaceuticals, LTD. | $166.12 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $140.31 | 2021-2023 | Onpattro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $129.66 | 2024 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $124.05 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $117.79 | 2019-2021 | |
| Amarin Pharma, INC. | $108.83 | 2020-2021 | |
| Baxter Healthcare | $81.52 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Medtronic Vascular, INC. | $35.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.67 | 2023 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $19.36 | 2020 | |
| Lantheus Medical Imaging, INC. | $17.22 | 2024 | |
| Boston Scientific Corporation | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Punit Sarna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.